BlackRock
ODT

BlackRock’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

BlackRock’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-400,914
Closed -$541K – 5993
2021
Q4 		$541K Sell
400,914
-330,583
-45% -$782K ﹤0.01% 4847
2021
Q3 		$2.13M Buy
731,497
+21,877
+3% +$72.7K ﹤0.01% 4299
2021
Q2 		$2.48M Sell
709,620
-886,612
-56% -$3.04M ﹤0.01% 4170
2021
Q1 		$5.46M Buy
1,596,232
+8,116
+0.5% +$153K ﹤0.01% 3906
2020
Q4 		$30.5M Buy
1,588,116
+686,652
+76% +$10.6M ﹤0.01% 2781
2020
Q3 		$12.1M Buy
901,464
+2,627
+0.3% +$74.4K ﹤0.01% 3120
2020
Q2 		$38.1M Buy
898,837
+135,020
+18% +$4.37M ﹤0.01% 2409
2020
Q1 		$21.1M Sell
763,817
-108,486
-12% -$3.16M ﹤0.01% 2575
2019
Q4 		$28.3M Buy
872,303
+6,251
+0.7% +$194K ﹤0.01% 2687
2019
Q3 		$22.5M Buy
866,052
+287,229
+50% +$9.61M ﹤0.01% 2747
2019
Q2 		$21.2M Buy
578,823
+206,238
+55% +$4.94M ﹤0.01% 2811
2019
Q1 		$8.24M Buy
372,585
+28,516
+8% +$499K ﹤0.01% 3204
2018
Q4 		$4.84M Buy
344,069
+5,244
+2% +$81.7K ﹤0.01% 3402
2018
Q3 		$6.58M Buy
338,825
+4,566
+1% +$93.1K ﹤0.01% 3409
2018
Q2 		$7.38M Buy
334,259
+50,138
+18% +$1.17M ﹤0.01% 3373
2018
Q1 		$6.02M Buy
+284,121
New +$6.7M ﹤0.01% 3364

Other funds holding ODT

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

BlackRock's ODT Position: Q1 2022 in Review

BlackRock sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q1 2022, closing a stake of 400,914 shares — an estimated $541K sold.

BlackRock first reported a position in ODT in Q1 2018 and held it in 16 quarters. The position peaked at $38.1M in Q2 2020. 8 funds tracked by Wall St. Rank hold ODT as of Q1 2022.

  • BlackRock reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • BlackRock sold 400,914 Odonate Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $541K.
  • BlackRock first reported a position in Odonate Therapeutics, Inc. Common Stock in Q1 2018 and held it in 16 quarters.
  • BlackRock's Odonate Therapeutics, Inc. Common Stock position peaked at $38.1M in Q2 2020.
  • 8 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q1 2022.

Based on BlackRock's 13F filing for Q1 2022, filed 12 May 2022.